Clincosm LogoSign in Get a demo

Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Sponsor
Albert Einstein Healthcare Network (Other)
Overall Status
Terminated
CT.gov ID
NCT02369744
Collaborator
(none)
1
Enrollment
1
Location
2
Arms
7
Duration (Months)
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Ureteral calculi, commonly known as kidney stones, are a frequent cause of Emergency Department (ED) visits. These stones can get caught in the ureter (the tube connecting the kidney to the bladder) and cause symptoms including pain, nausea, and vomiting. As long as the obstructing stone meets certain conditions and the patient isn't too sick, the patient is usually sent home to try and pass the stone without surgery. This treatment is known as medical expulsive therapy (MET), and routinely involves the use of a drug called tamsulosin, which relaxes the smooth muscle of the urinary system to help the stone pass. Silodosin is a drug in the same class of tamsulosin, but which is thought to have a more selective action and a quicker onset, which would theoretically make it better for aiding in kidney stone passage. The purpose of this study is a head-to-head, blinded comparison of these two drugs to see how quickly they result in stone passage. Subjects are patients presenting to the ED with acute kidney stone shown by CT scan, and who are appropriate for MET. The main study intervention is randomization to receiving either tamsulosin or silodosin. The hypothesis is that silodosin will have decreased time to stone passage compared to tamsulosin.

Subjects who qualify and consent are randomized to a two-week course of either silodosin or tamsulosin. They are also given prescriptions for standard of care medications for pain and nausea, as well as a pain diary. They receive a follow-up phone call after one week to remind them of their follow-up appointment, ask about adverse events, and determine if their stone has passed. They have a follow-up visit with study staff at the end of their two week treatment to collect their pain diary, pill count, adverse events, and to determine if their stone has passed. Study participation ends after this follow-up visit.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Procedures Involved in the Research. This study is a prospective, randomized, double-blinded, head-to-head trial comparing two medications. Patients with symptoms of renal colic who present to the emergency department will be evaluated by the ED staff as per usual routine. After a work-up (including routine chemistry, complete blood count, urine analysis, urine culture, and non-contrast CT scan of the abdomen and pelvis) has been completed, patients who meet inclusion criteria will be asked whether they are willing to enroll in the study. Those who are unsuitable for the study or unwilling to participate will continue to receive routine care for their ureteral calculus. Those who consent will be enrolled as subjects in the study, and given a 2-week supply of either tamsulosin or silodosin in blinded bottles with the appropriate dosing instructions. The prescriptions will be dispensed by the pharmacy; therefore the subjects and study staff will be blinded to which prescription the subject receives. Randomization will be done in advance and a key made to correlate subject enrollment number with which prescription they have received. Throughout the study, the study staff will make no efforts to ascertain which medication the subject has been given, unless an adverse event is suspected. Each participant will be given an information card that details the two possible medications they are taking, which can be presented to their physicians as needed.

Subjects will then be discharged to home as per routine care with instructions to drink plenty of fluids, and will be given a strainer and asked to attempt to catch their ureteral calculus. They will also be given a standardized prescription analgesic package (Percocet 5/325mg #20, Motrin 600mg #60, Zofran OD 4mg #20 with standard dosing instructions) and a Visual Analog Pain Scale diary to be filled out daily. Subjects will be given standardized discharge instructions as per standard of care that will include indications for immediate ED return for signs and symptoms of infection or MET failure (fever, worsening pain, vomiting, lethargy, unsteadiness, syncope or inability to tolerate oral pain medications). As per standard of care, they will be instructed to return to the ER immediately if they develop any of these symptoms. Finally, the subject's contact information will be collected at the time of enrollment and a follow-up appointment will be scheduled for them with Urology in 4 weeks to ensure they get appropriate and timely specialty follow-up. This follow-up is also standard of care, and will occur after the subject's participation in the study ends.

Each subject will be scheduled to return to the ER in 2 weeks to be seen by the research staff for data collection. They will be asked to bring their pill bottle and visual analog pain scale diary to this visit. If the subject reports having passed a stone consistent with their initial imaging, or have resolution of their pain to suggest they passed the stone unseen, this will conclude their participation in the study. However, if they are still having symptoms, their case will be categorized as an outpatient treatment failure and the subject will be registered to be seen by an ER Physician and a Urology consult will be ordered, concluding their participation in the study. This is current standard of care, and will be covered by insurance. Any subject that has an unscheduled visit to an ER for a ureterolithiasis-related complaint will also be considered an outpatient treatment failure. This will also conclude their participation in this study.

To ensure follow-up, subjects will be called one week after enrollment. They will be reminded of their 2-week follow-up appointment and the need to bring in their pill bottles. Each subject will also be asked if they have passed the stone or had resolution of the pain. The will be reminded that they must follow-up even if they are no longer having symptoms.

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy
Study Start Date :
Mar 1, 2013
Actual Primary Completion Date :
Oct 1, 2013
Actual Study Completion Date :
Oct 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Silodosin

Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.

Drug: Silodosin
8mg tablet, 1 tab PO daily for 2 weeks
Other Names:
  • Rapaflo

    		•
    Active Comparator: Tamsulosin

    Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.

    Drug: Tamsulosin
    0.4 mg Tab, 1 tab PO daily for 2 weeks
    Other Names:
  • Flomax

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Time to Stone Passage [at 2 weeks]

      The primary outcome measure will be the time it takes for the stone to pass. Stone passage will be defined as the subject self-reporting passage of a stone that is consistent with their imaging, or resolution of their pain to suggest unseen passage of their stone. This outcome will be measured from the initial emergency department visit, and gathered at the one-week follow-up call as well as the two-week follow-up visit.

    Secondary Outcome Measures

    1. Use of Pain Medication [at 2 weeks]

      The subject will be given a standardized pain medication prescription at their initial visit, and will be asked to keep track of how much pain medication they used each day, as well as to bring their pill bottle with them to the two-week follow-up appointment for a pill count. This information will be collected at the two-week follow-up appointment.

    2. Outpatient Treatment Failure [at 2 weeks]

      Subjects will be given instructions at the initial visit to return to the emergency department immediately for signs and symptoms of infection or MET failure (fever, worsening pain, vomiting, lethargy, unsteadiness, syncope or inability to tolerate oral pain medications). These subjects will be considered to have failed outpatient treatment and will be removed from the study. Subjects who do not experience these issues but who still report having symptoms at the two-week follow-up visit will also be considered to have failed outpatient treatment.

    3. Adverse Hemodynamic Reaction [at 2 weeks]

      Both tamsulosin and silodosin carry the possibility of causing orthostatic hypotension, which can manifest as unsteadiness, syncope, headache, and/or dizziness, especially when changing position from sitting/laying to standing. Subjects will be asked to assess themselves for these symptoms continuously from the initial visit, with serious reactions resulting in cessation of study medication. For reactions which are not serious, the information will be collected at the one-week follow-up call as well as the two-week follow-up visit.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Adults age 18 to 70 years

    • Non-diabetic

    • Unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter

    • Serum creatinine level within normal range

    • Ability to tolerate oral fluids and oral pain medication

    • Ability to make informed medical decisions regarding consent

    • Willingness to follow up in the ER in two weeks

    Exclusion Criteria:

    • Adults unable to consent

    • Age <18

    • Signs of infection including Temperature >38º C or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count

    5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of >100,000 CFU)

    • Patients with chronic pain already undergoing treatment with narcotic medications

    • Patients already taking an alpha adrenergic antagonist medication

    • Pregnant women

    • Prisoners

    • No working phone number

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Einstein Medical Center Philadelphia Philadelphia Pennsylvania United States 19141

    Sponsors and Collaborators

    • Albert Einstein Healthcare Network

    Investigators

    • Principal Investigator: William Boroughf, DO, Einstein Healthcare Network
    • Principal Investigator: James Gardner, MD, Einstein Healthcare Network

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Albert Einstein Healthcare Network
    ClinicalTrials.gov Identifier:
    NCT02369744
    Other Study ID Numbers:
    • HN 4441
    First Posted:
    Feb 24, 2015
    Last Update Posted:
    Jun 23, 2020
    Last Verified:
    May 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Albert Einstein Healthcare Network
    Ureteral calculus
    Ureterolithiasis
    Ureteral stone
    Kidney stone
    Medical expulsive therapy
    tamsulosin
    silodosin
    rapaflo
    flomax
    Additional relevant MeSH terms:
    Ureteral Calculi
    Ureterolithiasis
    Calculi
    Tamsulosin
    Silodosin

    Study Results

    Participant Flow

    Recruitment Details 0 Participants analyzed. PI has left the institution. Efforts made to contact the PI were unsuccessful. No study data available
    Pre-assignment Detail 0 Participants analyzed. PI has left the institution. Efforts made to contact the PI were unsuccessful. No study data available
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    Period Title: Overall Study
    STARTED 0 0
    COMPLETED 0 0
    NOT COMPLETED 0 0

    Baseline Characteristics

    Arm/Group Title Silodosin Tamsulosin Total
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks Total of all reporting groups
    Overall Participants 0 0 0
    Age () []
    <=18 years
    Between 18 and 65 years
    >=65 years
    Age () []
    Sex: Female, Male () []
    Female
    Male
    Region of Enrollment (participants) []

    Outcome Measures

    1. Primary Outcome
    Title Time to Stone Passage
    Description The primary outcome measure will be the time it takes for the stone to pass. Stone passage will be defined as the subject self-reporting passage of a stone that is consistent with their imaging, or resolution of their pain to suggest unseen passage of their stone. This outcome will be measured from the initial emergency department visit, and gathered at the one-week follow-up call as well as the two-week follow-up visit.
    Time Frame at 2 weeks

    Outcome Measure Data

    Analysis Population Description
    Data is not available
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    Measure Participants 0 0
    2. Secondary Outcome
    Title Use of Pain Medication
    Description The subject will be given a standardized pain medication prescription at their initial visit, and will be asked to keep track of how much pain medication they used each day, as well as to bring their pill bottle with them to the two-week follow-up appointment for a pill count. This information will be collected at the two-week follow-up appointment.
    Time Frame at 2 weeks

    Outcome Measure Data

    Analysis Population Description
    Data is not available
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    Measure Participants 0 0
    3. Secondary Outcome
    Title Outpatient Treatment Failure
    Description Subjects will be given instructions at the initial visit to return to the emergency department immediately for signs and symptoms of infection or MET failure (fever, worsening pain, vomiting, lethargy, unsteadiness, syncope or inability to tolerate oral pain medications). These subjects will be considered to have failed outpatient treatment and will be removed from the study. Subjects who do not experience these issues but who still report having symptoms at the two-week follow-up visit will also be considered to have failed outpatient treatment.
    Time Frame at 2 weeks

    Outcome Measure Data

    Analysis Population Description
    Data is not available
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    Measure Participants 0 0
    4. Secondary Outcome
    Title Adverse Hemodynamic Reaction
    Description Both tamsulosin and silodosin carry the possibility of causing orthostatic hypotension, which can manifest as unsteadiness, syncope, headache, and/or dizziness, especially when changing position from sitting/laying to standing. Subjects will be asked to assess themselves for these symptoms continuously from the initial visit, with serious reactions resulting in cessation of study medication. For reactions which are not serious, the information will be collected at the one-week follow-up call as well as the two-week follow-up visit.
    Time Frame at 2 weeks

    Outcome Measure Data

    Analysis Population Description
    Data is not available
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    Measure Participants 0 0

    Adverse Events

    Time Frame 0
    Adverse Event Reporting Description Data is not available: PI no longer at institution; attempts to contact unsuccessful
    Arm/Group Title Silodosin Tamsulosin
    Arm/Group Description Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks. Silodosin: 8mg tablet, 1 tab PO daily for 2 weeks Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks. Tamsulosin: 0.4 mg Tab, 1 tab PO daily for 2 weeks
    All Cause Mortality
    Silodosin Tamsulosin
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/0 (NaN) 0/0 (NaN)
    Serious Adverse Events
    Silodosin Tamsulosin
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/0 (NaN) 0/0 (NaN)
    Other (Not Including Serious) Adverse Events
    Silodosin Tamsulosin
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 0/0 (NaN) 0/0 (NaN)

    Limitations/Caveats

    0 Participants analyzed. PI has left the institution. Efforts made to contact the PI were unsuccessful. No study data available

    More Information

    Certain Agreements

    All Principal Investigators ARE employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/Title Kamran Mohiuddin; Director ED Clinical Research
    Organization Albert Einstein Medical Center
    Phone 2154562313
    Email MOHIUDDK@EISNTEIN.EDU
    Responsible Party:
    Albert Einstein Healthcare Network
    ClinicalTrials.gov Identifier:
    NCT02369744
    Other Study ID Numbers:
    • HN 4441
    First Posted:
    Feb 24, 2015
    Last Update Posted:
    Jun 23, 2020
    Last Verified:
    May 1, 2017